Hepatol Int. 2010 Jul 31;4(3):577-84. doi: 10.1007/s12072-010-9197-z.
To evaluate the sequence variations in the enhancer II (EnhII)/basal core promotor (BCP)/precore (PC) and X genes of hepatitis B virus (HBV) in Thai patients with hepatocellular carcinoma (HCC) by conducting a cross-sectional case-control study.
As much as 60 patients with HCC and 60 patients without HCC, who were matched for sex, age, hepatitis B e antigen (HBeAg) status, and HBV genotype, were included. Viral mutations in the EnhII/BCP/PC and X regions were characterized by direct sequencing in serum samples.
The prevalence of T1753C/A, A1762T/G1764A and G1899A mutations were significantly higher in the HCC group compared to the non-HCC group (43.3 vs. 23.3%, P = 0.02; 88.3 vs. 53.0%, P < 0.001; and 35.0 vs. 8.3%, P = 0.001, respectively). No significant difference between groups was found with respect to G1613A, C1653T, C1766T/T1768A, A1846T/C, T1858C, and G1896A mutations. By multiple logistic regression analysis, the presence of cirrhosis, A1762T/G1764A and G1899A mutations were independently associated with the risk of HCC.
These data suggested that A1762T/G1764A and G1899A mutations were associated with the development of HCC in Thai patients.
通过病例对照研究，评估泰国肝细胞癌（HCC）患者乙型肝炎病毒（HBV）增强子 II（EnhII）/基本核心启动子（BCP）/前核心（PC）和 X 基因的序列变异。
纳入 60 例 HCC 患者和 60 例性别、年龄、乙型肝炎 e 抗原（HBeAg）状态和 HBV 基因型匹配的无 HCC 患者。通过直接测序检测血清样本中 EnhII/BCP/PC 和 X 区的病毒突变。
与非 HCC 组相比，HCC 组 T1753C/A、A1762T/G1764A 和 G1899A 突变的发生率明显更高（43.3%比 23.3%，P=0.02；88.3%比 53.0%，P<0.001；35.0%比 8.3%，P=0.001）。两组间 G1613A、C1653T、C1766T/T1768A、A1846T/C、T1858C 和 G1896A 突变无显著差异。多因素逻辑回归分析显示，肝硬化、A1762T/G1764A 和 G1899A 突变与 HCC 的发生风险独立相关。
这些数据表明，A1762T/G1764A 和 G1899A 突变与泰国患者 HCC 的发生有关。
